Risk factor
Very high price volatility
Profitability factor
Strong growth
About
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an...
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. In particular, the stock is underpriced on P/E, 'expensive' on EV/EBITD
Target Price
The average target price of TGTX is 46 and suggests 66% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell